Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 7, 2025
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
GlobeNewswire
·
May 7, 2025
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. ( …
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
May 7, 2025
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of …
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire
·
May 7, 2025
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for …
Arialief Complaints Explained: 2025 Customer Reviews Analyzed & Verified
GlobeNewswire
·
May 7, 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- In 2025, nerve pain remains one of the most widespread yet under-discussed health challenges. Clinically known as peripheral neuropathy, this condition affects millions worldwide and manifests in various forms, …
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
GlobeNewswire
·
May 7, 2025
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., …
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
GlobeNewswire
·
May 7, 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
GlobeNewswire
·
May 7, 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in …
Thérapeutique Knight annonce la relance de ONICIT® au Brésil et au Mexique
GlobeNewswire
·
May 7, 2025
MONTRÉAL, 07 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd'hui la prise en charge complète des activités commerciales et la relance de …
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire
·
May 7, 2025
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at …
Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC …
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline …
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
GlobeNewswire
·
May 7, 2025
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination …
The Joint Corp. to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced that President and CEO Sanjiv Razdan and CFO Jake Singleton are scheduled to participate in …
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire
·
May 7, 2025
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter …
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
GlobeNewswire
·
May 7, 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
GlobeNewswire
·
May 7, 2025
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
GlobeNewswire
·
May 7, 2025
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation …
Immunocore reports first quarter financial results and provides a business update
GlobeNewswire
·
May 7, 2025
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On …
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
GlobeNewswire
·
May 7, 2025
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …